dr. mato discusses the safety and efficacy of umbralisib in cll
Published 6 years ago • 492 plays • Length 1:29Download video MP4
Download video MP3
Similar videos
-
2:04
dr. mato discusses a phase ii trial of umbralisib in cll
-
1:12
dr. mato on immunotherapy options in cll
-
0:59
dr. mato on the use of biosimilars in cll
-
1:10
dr. mato on the cll14 trial results in cll
-
1:29
dr. anthony mato on the difference between intolerance and resistance in cll
-
0:45
dr. mato discusses the benefits of the jtcc retrospective trial
-
1:40
dr. mato on utilizing car t cells in cll
-
1:50
dr. mato on ibrutinib versus acalabrutinib in cll
-
0:47
dr. davids on the potential utility of frontline ibrutinib/umbralisib in mcl and cll
-
1:09
dr. ghia on efficacy and safety of acalabrutinib in relapsed/refractory cll
-
1:55
umbralisib and ublituximab in patients with cll and comorbidities
-
1:39
umbralisib plus ublituximab vs. standard of care chemoimmunotherapy in cll
-
1:04:14
watch drs. mato & shah discuss the latest in btk inhibitors: participate here https://bit.ly/3k6ajg9
-
4:54
umbralisib, ublituximab and venetoclax in patients with relapsed or refractory chronic lymphocyt...
-
0:47
dr. davids on remaining questions with umbralisib/ibrutinib in cll and mcl
-
1:22
dr. davids on updated data with ibrutinib/umbralisib in r/r cll and mcl
-
8:37
safety and efficacy of cd7-targeted car-t therapy in patients with r/r t-all and t-lbl
-
2:01
ublituximab, umbralisib and ibrutinib in cll and nhl
-
50:25
the latest cll treatments and therapies with dr jan burger